A peer-reviewed study has demonstrated that Cumulus Neuroscience’s NeuLogiq platform can be used successfully by people living with mild Alzheimer’s disease dementia to complete cognitive assessments and electroencephalography (EEG) monitoring at home over a 12-month period.

The findings, published in Frontiers in Digital Health, are based on results from the CNS-101 study, which evaluated the feasibility and usability of the digital platform in patients with mild Alzheimer’s disease dementia and healthy older adults.

The study enrolled 119 participants across seven clinical sites in the UK, including 59 people with mild Alzheimer’s disease dementia and 60 age-matched healthy controls. Following a single in-clinic training session, participants completed EEG recordings and tablet-based cognitive assessments independently at home over 52 weeks.

Researchers reported high levels of adherence throughout the study. Patients with Alzheimer’s disease dementia maintained 77% adherence to the year-long protocol and completed 99.7% of the assessment sessions they started. Healthy control participants achieved an adherence rate of 88.8%.

The study is the first to evaluate the NeuLogiq platform in patients diagnosed with Alzheimer’s disease dementia. The authors said the findings support the feasibility of collecting objective digital biomarkers, including measures of cognition, brain activity and sleep, in patients’ homes over extended periods.

Professor James Rowe, professor of cognitive neurology at the University of Cambridge and principal investigator of the CNS-101 study, said: “What this study shows is that frequent, objective measurement of brain activity and cognition can be moved into the patient’s home — including those living with dementia — and sustained over a year with high adherence and real acceptability. Collecting data in a familiar environment, free of the stress and fatigue of lengthy clinic visits, is not only more comfortable for patients and families — it is a necessary step toward more sensitive, patient-friendly endpoints for the next generation of Alzheimer’s trials.”

The researchers noted that current clinical trial endpoints for Alzheimer’s disease, including the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating scale, rely on relatively infrequent clinic-based assessments that may be less sensitive to subtle changes in cognition. More frequent home-based monitoring could provide a more detailed picture of disease progression while reducing the burden associated with repeated clinic visits.

The NeuLogiq platform combines a wireless dry-sensor EEG headset with tablet-based cognitive assessments and integrates additional measures of mood, speech and sleep. The study was designed to evaluate feasibility and usability rather than treatment effects.

According to the authors, the ability to collect frequent objective measurements outside the clinic could improve the design of future Alzheimer’s disease clinical trials by providing more reliable longitudinal data and potentially reducing the number of participants or duration required to detect treatment effects.

The research was funded by Innovate UK and the platform was developed with input from a pharmaceutical advisory group comprising companies involved in neuroscience drug development.